Centralized procurement of Chinese patent medicines is here again, and a large number of medicines will be reduced in price

Recently, the Hubei Province Pharmaceutical Price and Bidding and Purchasing Management Service Network issued the “Announcement of the Centralized Procurement of Chinese Patent Medicines by the Inter-provincial Alliance (No.
1)”, which shows that Hubei Province will join 18 provinces including Hebei, Shanxi, and Inner Mongolia to carry out the centralized procurement of Chinese patent medicines.
Quantity purchase
.
The announcement shows that the proprietary Chinese medicines collected this time include Xueshuantong, Bailing, Danshen, Shuanghuanglian and other 17 product groups and 76 medicines, which belong to the Chinese patent medicines produced by many companies with large clinical use, high purchase amount.
It mainly involves diseases such as cardiovascular, urinary system and so on
.
The procurement entities include all public medical institutions in the alliance area, and the designated social medical institutions and designated pharmacies of medical insurance are encouraged to participate in accordance with the relevant regulations of the alliance area
.
The extent of price cuts for centralized procurement has always been the focus of public attention
.
Regarding the results of the centralized procurement of Chinese patent medicines in Hubei Province, industry analysts believe that compared with the previous chemical drug procurement, the shock to the industry caused by the centralized procurement of Chinese patent medicines will be relatively small, and the price reduction is expected to be 20%-30%
.
The reason for this conclusion is that if the price cut is too large, it may cause companies to use low-quality Chinese medicinal materials
.
Especially in the context of the large price increase of Chinese herbal medicine raw materials this year, the quality and efficacy of Chinese patent medicines largely depend on the quality of Chinese medicinal materials.
The same generic name medicine made with different Chinese medicinal materials will have greater efficacy.
Difference
.
It is worth noting that this centralized procurement is not an exception
.
As early as August this year, the National Medical Insurance Administration made it clear that it would start with high-priced and large-volume varieties and scientifically and steadily advance the reform of centralized procurement of Chinese patent medicines and formula granules
.
Prior to this, the Guangdong Provincial Pharmaceutical Trading Center also issued a document stating that it planned to carry out a large-scale procurement of alliance regional groups for 58 drugs including Qingkailing
.
Wherein the 58 varieties includes 36 exclusive proprietary varieties, comprising CSDP, Lianhuaqingwen product Naoxintong capsule, soy children Alice heat particles, Tanreqing, Zishen tire balls
.
It is reported that the alliance regions participating in this collection of varieties report will include Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai, and Xinjiang..
In the context of the continuous advancement of centralized procurement of Chinese patent medicines, the industry expects that mass procurement of Chinese patent medicines may cause short-term disturbances to market sentiment, but in the long run, centralized procurement of medicines will help clear the industry and intensive development; at the same time, It will also benefit companies with high-quality resources and promote further industry concentration
.
At present, the general trend of centralized procurement of Chinese patent medicines in the industry has become a general trend, and many Chinese patent medicine companies are taking precautions and are beginning to make various preparations
.
For example, Zuoli Pharmaceuticals previously replied to investors on the interactive platform that the implementation of a centralized procurement policy is the general trend, and the company will actively respond to policy changes
.
With the increasing development of psychosomatic medicine, doctors and patients can use Wuling capsules and other traditional Chinese medicines according to the needs of disease treatment.
The company expands its market share and serves more people through hospital development, department development, OTC and Internet e-commerce expansion.
, Increase the company's main business income
.
Xiangxue Pharmaceutical also stated in the 2021 semi-annual report that the company is extending the industrial chain upward by actively deploying Chinese medicinal material production bases, increasing the self-sufficiency of raw materials in the Chinese patent medicine business, and strengthening the supply of raw materials and quality assurance
.
At present, it has established production bases of Chinese medicinal materials in Ningxia, Shanxi, Sichuan, Yunnan, Hubei, Guangdong and other places
.